Abbott Laboratories stock: Leerink upgrades rating and target
Published on 11/21/2026 at 11:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst view and pipeline
- Leerink Partners cited a refreshed MedTech outlook and updated analysis behind its more constructive view.
- The rating change adds a new analyst signal as Abbott continues to develop its medical-device portfolio.
Leerink Partners upgraded Abbott Laboratories from Market Perform to Outperform on November 19, according to Markets Insider. The analyst also raised its price target to 124 US dollars from 106 US dollars.
Leerink takes a more constructive view
The firm pointed to a refreshed outlook on the medical-technology sector and updated analysis. Leerink said its conviction had increased that MedTech could deliver outsized returns over the next 12 to 24 months as several supportive factors converge.
Abbott operates across medical devices, diagnostics, nutrition and established pharmaceuticals. For investors, the upgrade adds an external assessment of the company's prospects while the medical-device portfolio remains a central part of the investment case.
Saturday quote remains below Thursday close
Abbott Laboratories stock traded at 93.91 euros on Lang & Schwarz at 11:16 CET on Saturday, November 21, 1.73 percent below the Xetra close of Thursday, November 19. The comparison uses the 95.56-euro Xetra close reported by Yahoo Finance.
Abbott Laboratories at a glance
- Company: Abbott Laboratories
- ISIN: US0028241000
- Lang & Schwarz quote: 93.91 euros at 11:16 CET on November 21, 2026
- Xetra close: 95.56 euros on November 19, 2026
- Analyst change: Leerink Partners raised the rating from Market Perform to Outperform on November 19, 2026
- Price target: 124 US dollars, up from 106 US dollars
Current market developments can be followed in the Current market reports.
More news and analyses on Abbott Laboratories stock.
